GNT Biotech & Medicals (TPEX:7427) - Share price, News & Analysis

7427 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

7427 Stock Overview

GNT Biotech & Medicals Corporation develops drugs to treat advanced and refractory cancers.

Risk Analysis

Makes less than USD$1m in revenue (NT$630K)

Does not have a meaningful market cap (NT$831M)

GNT Biotech & Medicals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GNT Biotech & Medicals
Historical stock prices
Current Share Price	NT$36.80
52 Week High	NT$100.00
52 Week Low	NT$32.85
Beta	0
1 Month Change	-0.67%
3 Month Change	-13.00%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-43.82%

Shareholder Returns

	7427	TW Biotechs	TW Market
7D	-1.2%	-0.9%	2.0%
1Y	n/a	7.6%	-0.2%

Return vs Industry: Insufficient data to determine how 7427 performed against the TW Biotechs industry.

Return vs Market: Insufficient data to determine how 7427 performed against the TW Market.

Price Volatility

Is 7427's price volatile compared to industry and market?
7427 volatility
7427 Average Weekly Movement	3.7%
Biotechs Industry Average Movement	5.2%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.2%
10% least volatile stocks in TW Market	2.2%

Stable Share Price: 7427 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 7427's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2013	13	Chia-Nan Chen	https://www.gntbm.com.tw/tw

GNT Biotech & Medicals Corporation develops drugs to treat advanced and refractory cancers. It develops drugs for epigenetic modulators, epiimmune modulators, tumor microenvironment modulators, and HDACs 1, 2, 3 protein degrading agents. GNT Biotech & Medicals Corporation was formerly known as GNT Biotech Corporation and changed its name to GNT Biotech & Medicals Corporation in October 2013.

GNT Biotech & Medicals Fundamentals Summary

How do GNT Biotech & Medicals's earnings and revenue compare to its market cap?
7427 fundamental statistics
Market Cap	NT$830.76m
Earnings (TTM)	-NT$35.86m
Revenue (TTM)	NT$630.00k

1,319x

P/S Ratio

-23.2x

P/E Ratio

Is 7427 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
7427 income statement (TTM)
Revenue	NT$630.00k
Cost of Revenue	NT$347.00k
Gross Profit	NT$283.00k
Other Expenses	NT$36.14m
Earnings	-NT$35.86m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.59
Gross Margin	44.92%
Net Profit Margin	-5,691.59%
Debt/Equity Ratio	0.0%

How did 7427 perform over the long term?

See historical performance and comparison

Valuation

Is GNT Biotech & Medicals undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

3.99x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 7427's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 7427's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 7427 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 7427 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 7427's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 7427 is overvalued based on its PB Ratio (4x) compared to the TW Biotechs industry average (3.8x).

Future Growth

How is GNT Biotech & Medicals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

126.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GNT Biotech & Medicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has GNT Biotech & Medicals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-14.7%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: 7427 is currently unprofitable.

Growing Profit Margin: 7427 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 7427's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 7427's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7427 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).

Return on Equity

High ROE: 7427 has a negative Return on Equity (-17.21%), as it is currently unprofitable.

Financial Health

How is GNT Biotech & Medicals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 7427's short term assets (NT$125.4M) exceed its short term liabilities (NT$21.6M).

Long Term Liabilities: 7427 has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: 7427 is debt free.

Reducing Debt: 7427 had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 7427 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 7427 has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 23.5% each year.

Dividend

What is GNT Biotech & Medicals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 7427's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 7427's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 7427's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 7427's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 7427 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Chia-Nan Chen

6.33yrs

Tenure

Dr. Chia-Nan Chen serves as Chairman and President of GNT Biotech & Medicals Corporation. In 2013, Dr. Chen was one of the founders of GNTbm. Dr. Chen studied Pharmacology and is a board certified pharmaci...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: 7427 only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2022/05/21 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31